After serving as editor-in-chief of Nanomedicine: Nanotechnology, Biology and Medicine for over seven years, Lajos Balogh knew that he had the skills and expertise needed to run an academic journal. An ardent open access (OA) advocate, Balogh...
Read moreHighlighted presence of VHIR researchers at the 11th Jornada de Recerca de l’ICS
On May 23, 2019, the Centre Tarraconense El Seminari will host the 11th Research Day organized by the Catalan Health Institute involving several researchers from the Vall d’Hebron Research Institute (VHIR). This year, is dedicated to...
Read moreSecond mini-symposium on Cancer Research Omics
The Vall d’Hebron Research Institute’s Oncology Department (VHIR) has organized the second mini-symposium ‘OMICs in Cancer Research’ in which speakers from different institutions and countries, reviewed the current state...
Read moreMarch 31, World Colorectal Cancer Day
On the occasion of World Colorectal Cancer Day, this Sunday, March 31, CIBBIM-Nanomedicine. Biomedical Research in Digestive Tract Tumors of the Institut de Recerca Vall d’hebron (VHIR) wants to raise awareness among the population about...
Read moreVall d’Hebron organizes a seminar on Lysosomal Rare Disorders: Focus on Fabry Disease
Next Monday, November 19, Vall d’Hebron will hold a seminar focused on Lysosomal Rare Disorders: Focus on Fabry Disease. The seminar is part of the Rare Diseases Program at the Vall d’Hebron Campus, in collaboration with the European...
Read moreVHIR researchers receive European funding for liver disease research
Dr. Joan Genescà, head of the Liver Diseases research group and Dr. María Martell, group researcher and head of the Advanced Liver Disease laboratory, from the Liver Diseases group at VHIR, have received funding for a European research project in...
Read moreThe EMA designates a new orphan drug for Fanconi anemia in whose development VHIR has participated
The European Commission, upon proposal from the European Medicines Agency (EMA), has designated Gefitinib as an orphan drug for Fanconi anemia. This orally administered product is currently indicated for the treatment of lung cancer. The studies...
Read moreCIBBIM Nanomedicine awarded at the National Congress of Paediatric Nephrology
Pre-doctoral researcher Mónica Vall, from the research group in Renal Physiopathology – CIBBIM Nanomedicine led by Dr. Anna Meseguer, won the prize for the best poster – short communication from the XLIII National Congress of...
Read moreDr. J. Raúl Herance, appointed Co-chair of the Spanish Group of the European Molecular Imaging Society
Recently, Dr. J Raúl Herance, co-head of the Molecular Medical Imaging group at the Vall d’Hebron Research Institute (VHIR) has been elected to the position of Co-chair of the Spanish Group of the European Molecular Imaging Society. It will...
Read moreA new European project awarded to the CIBBIM-Nanomedicine of the VHIR converts the Vall d’Hebron Campus into the health institution with the highest number of active research projects in Nanomedicine of Europe
For the first time, the Vall d’Hebron Campus has a FET Innovation (Future and Emerging Technologies) project that has been awarded within the Horitzo 2020 program to the CIBBIM-Nanomedicine. Drug Delivery and Targeting research group...
Read moreThe EVO-NANO project will allow testing the behavior of nanoparticles within a tumor
The CIBER-BBN-CIBBIM group, led by Dr. Simó Schwartz, coordinating NANBIOSIS U20. In Vivo Experimental Platform has been granted a FET Innovation project (Future and Emerging Technologies) within the Horizon 2020 program. The EVO-NANO project...
Read moreApril, Fabry disease awareness month
The Fabry International Network (FIN) association has established the month of April as the «month of Fabry» to raise awareness and educate about this disease, a rare, progressive and with multi-organ involvement pathology. Fabry disease is a...
Read more